EUVIMEDEUVIMED entdecken
Editorial

HDL Therapeutics — Time for a Curtain Call or Time to Reconceptualize?

Christie M Ballantyne, Vijay Nambi

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2403036 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Christie M Ballantyne und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medicine, Baylor College of Medicine (C.M.B., V.N.), the Texas Heart Institute (C.M.B.), and the Department of Medicine, Micha…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cholesterol, HDL, Hypolipidemic Agents, Lipid Metabolism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of an inverse association between high-density lipoprotein (HDL) cholesterol levels and incident cardiovascular disease events, 1 combined with research on the role of HDL in reverse cholesterol transport, led to the exploration of therapies directed toward increasing HDL cholesterol. However, although therapies such as cholesteryl-ester transfer protein inhibitors increased HDL cholesterol levels, these therapies did not reduce the incidence of cardiovascular disease events. 1,2 Consequently, the focus of HDL therapeutics shifted to attempting to improve the functionality, or quality, of HDL, and efforts to measure and enhance cholesterol efflux capacity and thereby promote reverse cholesterol transport were initiated. 1,2 Although the . . .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCholesterol, HDLHypolipidemic AgentsLipid MetabolismHumansBiological TransportCholesterol Ester Transfer ProteinsRandomized Controlled Trials as TopicLipoproteins, HDL

Substanzen

Cholesterol Ester Transfer ProteinsCholesterol, HDLHypolipidemic AgentsCSL112Lipoproteins, HDL

Autor:innen und Institutionen

  • From the Department of Medicine, Baylor College of Medicine (C.M.B., V.N.), the Texas Heart Institute (C.M.B.), and the Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center (V.N.) - all in Houston.

Zitieren

APA

Ballantyne, C. M., & Nambi, V. (2024). HDL Therapeutics — Time for a Curtain Call or Time to Reconceptualize?. New England Journal of Medicine. https://doi.org/10.1056/nejme2403036

Vancouver

Ballantyne CM, Nambi V. HDL Therapeutics — Time for a Curtain Call or Time to Reconceptualize?. New England Journal of Medicine. 2024. doi:10.1056/nejme2403036

BibTeX
@article{Ballantyne2024,
  author = {Ballantyne, Christie M and Nambi, Vijay},
  title = {HDL Therapeutics — Time for a Curtain Call or Time to Reconceptualize?},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2403036}
}
Kostenlos starten →